Replies to post #47933 on BioStem Technologies Inc. (BSEM)

[flaflyersfan]

New Management of Biostem Technologies
(BSEM) Announces Name and Symbol Change to
Be in Effect Today; BSEM Also Moves Forward to
Complete an Interactive Webpage and Will Be
Attending the 22nd Annual World Congress on
Anti-Aging Medicine Dec 11-13, 2014
OAKLAND PARK, FL--(Marketwired - December 09,
2014) - Biostem Technologies, Inc. (OTC PINK:
BSEM) (BSEM), is pleased to announce the Financial
Industry Regulatory Agency (FINRA) has approved a
name and symbol change from Caribbean
International Holdings, Inc. to Biostem Technologies,
Inc. ( BSEM) effective today. The new management
believes this name will reflect Biostem Technologies,
Inc.'s new focus.
Biostem Technologies, Inc. is an emerging
Regenerative Medicine company with a vast amount
of scientific and clinical knowledge; this knowledge
allows ( BSEM) to effectively treat patients, explore
cutting edge protocols and develop breakthrough
treatments. Biostem Technologies, Inc. is focused on
evolving the emerging Stem Cell industry with
innovative protocols for treatment in an array of rare
and common degenerative diseases.
Biostem Technologies, Inc. is also excited to
announce its progress on its new interactive website
currently in production. This web page will include;
but not limited to, a look at our facilities, doctors, and
informative articles on stem cell therapy and
regenerative medicine. In addition to the website
Biostem Technologies, Inc. has launched a new
Twitter page ( @biostemtech) to help keep the public
informed of upcoming news and events.
Biostem Technologies, Inc. management along with
Dr. Rafael Gonzalez, will also be attending the 22nd
Annual World Congress on Anti-Aging Medicine. The
A4M conference is taking place in Las Vegas, NV on
December 11-13th. Dr. Gonzalez has become a key
opinion leader in the biomedical industry and has
expansive knowledge on the behavior and expansion
of stem cells and stem cell cryopreservation. His
research includes stem cell applications for multiple
diseases, degenerative disorders and research on the
behavior of stem cell cultures and cell biology from
several development stages.
About Cryopreservation & Culture Expansion of
Stem Cells:
Mesenchymal stem cells (MSCs) may be isolated
from tissues such as adipose, bone marrow,
umbilical cord tissue and blood. Following tissue
processing, you will have the option of using your
mixed cell product, such as stromal vascular fraction
or purification of MSCs by expansion in culture. In
2006, there was a set of guidelines defining MSCs.
One of the main characteristics is the ability to
adhere to plastic. For cells to adhere to plastic, they
require culture expanding MSCs and eventual
cryopreservation. We will discuss methods of culture
expansion and cryopreservation of MSCs. We will
overview the use of the reagents necessary to start
and expand MSCs. In addition, we will analyze
methods of mesenchymal stem cell culture
expansion and their implications in patient
treatment. We will also discuss the importance and
logistics of the cryopreservation process for your
expanded MSCs.
About The American Academy of Anti-Aging
Medicine (A4M):
The American Academy of Anti-Aging Medicine (A4M)
is a US federally registered 501(c) 3 non-profit
organization comprised of over 26,000 members
including: physicians, health practitioners, scientists,
government officials, and members of the general
public, representing over 110 nations.
The A4M is dedicated to the advancement of
technology to detect, prevent, and treat aging related
diseases and to promote research into methods to
retard and optimize the human aging process. The
A4M is also dedicated to educating physicians,
scientist, and members of the public on biomedical
sciences, breaking technologies, and anti-aging
issues.
About Biostem Technologies, Inc. (BSEM):
Biostem Technologies, Inc. is a holding company
for Regenerative Bio Science, Inc. ("RBSI"). The
Company subsidiary RBSI is focused on helping
individuals protect and ensure their future quality of
life through Adult and/or Cord Blood Stem Cell
Incubation and the practice of regenerative medicine
in the United States and the Dominican Republic.
RBSI's mission is not only to allow patients to store
their Stem Cells for future use, but also perform
patient funded stem cell therapies from sports
injuries to degenerative diseases such as MS,
Arthritis, Degenerative Heart Diseases, Diabetes and
a host of experimental therapies in the brain trauma
disease sector including CTE. The goal is to become a
global leader in establishing protocols that can be
patented and utilized to heal patients around the
world.
Stem cells work as the repairmen of the body by
replenishing and regenerating damaged tissues and
cells. Certain conditions have shown marked
improvement when treated with stem cells taken
from the patient's own body as well as Cord Blood
stem cells. Regenerative Bioscience is becoming part
of a revolution in healthcare using stem cells.
Forward-Looking Statements Except for statements of
historical fact, the matters discussed in this press
release are forward looking and made pursuant to
the Safe Harbor provisions of the Private Securities
Litigation Reform Act of 1995. "Forward-looking
statements" describe future expectations, plans,
results, or strategies and are generally preceded by
words such as "future," "plan" or "planned,"
"expects," or "projected." These forward-looking
statements reflect numerous assumptions and
involve a variety of risks and uncertainties, many of
which are beyond the company's control that may
cause actual results to differ materially from stated
expectations. These risk factors include, among
others, limited operating history, difficulty in
developing, exploiting and protecting proprietary
technologies, intense competition and additional
risks factors as discussed in reports filed by the
company with the Securities and Exchange
Commission, which are available on at http://
www.sec.gov.
Contact:
Biostem Technologies, Inc.
Phone: [phone]
Website: http://www.biostemtech.com
Email: [e-mail]
Twitter: @Biostemtech